Victorium Clinical Research | Houston, TX

Research site

(Unclaimed)

Location

929 Gessner Road, Suite #2450, Houston, Texas, United States of America

Site insights

Top conditions

Top treatments

Sugar

TAK-279

NNC0487-0111

Finerenone

Empagliflozin

Rimegepant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 7 total trials

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type...

Enrolling

Type 2 Diabetes (T2D)

Drug: Placebo (NNC0487-0111 oral)

Drug: NNC0487-0111 oral

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be inv...

Enrolling

Diabetes, Type 2

Drug: Insulin glargine

Drug: Insulin icodec

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate t...

Enrolling

Crohn's Disease

Drug: Placebo

Drug: TAK-279

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical...

Enrolling

Ulcerative Colitis

Drug: TAK-279

Drug: Placebo

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE)

Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known...

Active, not recruiting

Chronic Kidney Disease

Type 2 Diabetes Mellitus

Drug: Finerenone (BAY94-8862 ) 20 mg

Drug: Finerenone Placebo